Mr. Zohar Krivorot of Cannara reports

CANNARA EXPANDS INTERNATIONAL SUPPLY AGREEMENT WITH CURALEAF

Cannara Biotech Inc. has expanded its long-term international supply agreement with Curaleaf Holdings Inc.'s Curaleaf International Ltd., previously announced on July 14, 2026. If fully realized, the amended agreement has a potential aggregate contract value of approximately $34-million over its two-year term, compared with up to $21-million under the original agreement, based on committed supply volumes and the terms and conditions of the agreement. The expanded relationship builds on Cannara's first long-term international supply commitment and provides an opportunity to grow international sales through Curaleaf's established distribution network while continuing to support the company's Canadian growth strategy.

"The expansion of our agreement reflects the strong relationship we are building with Curaleaf and the quality of the cannabis we have supplied from our Valleyfield facility," said Zohar Krivorot, founder and chief executive officer of Cannara. "We see a meaningful opportunity to grow together as partners, supplying Quebec-grown cannabis to international medical markets while continuing to execute our growth strategy here in Canada."

"This expanded agreement demonstrates our ability to grow within the cultivation infrastructure we already own at Valleyfield, where we now have 15 of our 24 grow rooms active," said Niko Sosiak, chief operating officer of Cannara. "With a fully funded buildout plan, our remaining capacity gives us a clear runway to scale production as demand grows, while maintaining consistent quality and the cost discipline that support our growth in Canada and internationally."

Curaleaf also continues to support Cannara's pursuit of EU-GMP (European Union good manufacturing practice) certification for its processing center at Valleyfield. In the interim, cannabis flower supplied under the agreement will be dried and processed under EU-GMP conditions at Curaleaf's EU-GMP certified facility in Canada before release into international medical markets.

About Cannara Biotech Inc.

Cannara Biotech is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products. Cannara owns two mega facilities based in Quebec spanning over 1.6 million square feet, providing the company with 100,000 kilograms of potential annualized cultivation output. Leveraging Quebec's favourable energy costs, Cannara maintains an efficient, low-cost production model.

About Curaleaf Holdings Inc.

Curaleaf Holdings is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. Curaleaf International's unique distribution network throughout Europe, Canada, and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production.

We seek Safe Harbor.